Columbia University

Technology Ventures

CTV Executives in Residence

CTV’s Executive in Residence (XIR) Program aims to connect Columbia inventors and technologies with seasoned industry executives, venture capitalists, and serial entrepreneurs. By doing so, we hope to leverage the deep domain expertise of these individuals to help accelerate the path of these promising technologies towards market success. XIRs are encouraged to develop close ties with our inventors, entrepreneurs, and technology transfer team in order to help Columbia further develop these technologies. If you are a Columbia researcher and would be interested in meeting with a CTV XIR, please email techventures@columbia.edu.

Current CTV Executives in Residence

Linda Dujack

Area of expertise: 
Biomedical
Johnson & Johnson, FDA, Hoffman-La Roche, National Academy of Sciences
Year Served: 
Bio 

Linda Dujack, retired from Johnson & Johnson (J&J), was Vice President for Product Evaluation and University Relations, where she was responsible for proactively establishing relationships with universities, small bio-tech companies, and major pharmaceutical companies in order to identify new opportunities that would merit participation by J&J.

Prior to that Linda served as Vice President of Worldwide Regulatory Affairs at J&J, resulting in many successful submissions and approvals. She was also part of the licensing/financing team responsible for evaluating new product/technology opportunities and developing R&D cost models for the financial evaluation of these opportunities. At J&J Linda also served as Executive Director for the Erythropoietin (EPO) Worldwide Development Project and Director for Medical Services and Support, a department she established for Ortho Biotech.

Prior to joining J&J, Linda was Deputy Director for the Food and Drug Administration in the Center for Biologics Evaluation and Research. She was also Vice President for Regulatory Affairs and Special Projects at Geritech, a small start-up company whose technology came from Rockefeller University. Linda was also Associate Director of Regulatory Affairs at Hoffmann La-Roche. Prior to that she was a Senior Staff Officer at the National Academy of Sciences/Institute of Medicine.

Linda earned her PhD in biology from Georgetown University with distinction and her BS degree also in biology from Ramapo College of New Jersey with honors. She taught biology and cell biology as an Assistant Professor at Hood College in Frederick, MD.

Charles Goldstein

Becton Dickinson, Millipore Corp
Year Served: 
Bio 

Since retiring from Becton Dickinson (BD) in Jan 2016, Charles has been acting as a strategic advisor to large and medium companies seeking to expand further into or enter the Health Care market. Charles also serves as Board member for innovative start up companies. On the investment side, Charles is a seed stage angel investor. Overall Charles expertise covers technology, business and go to market strategy and also deep knowledge of product development for medical devices, diagnostics and life science research tools.

From October 2013 to Jan 2016 Charles was Sr. Vice President / Chief Scientific Officer Greater Asia, responsible for the strategy and global performance of BD’s regional R&D operations in Asia. The strategic goal was to enhance the companies’ growth in emerging countries via market appropriate solutions. A lucrative Regional pipeline was created, a fully functional R&D operation was created in China and the existing Singapore capability was expanded to enable product development and responsibility as the Regional R&D hub. An extensive external network was established that enabled sourcing and deal making for new opportunities from start ups, Universities and other companies. In 1997 Charles was appointed BD's Vice President, Research responsible for BD Technologies. BD Technologies engages in technology development in support of downstream product development carried out by the businesses. Some of BD Technologies accomplishments include commercialized micro needle based drug delivery, nano- technology based point of care diagnostics and novel products for stem cell growth. Extensive external networking and partnering was done to tap outside innovation.

In addition, Charles has championed and introduced new Innovation practices on a global basis. Charles established in-house incubators in NC and Singapore for collaboration with and investment in start-ups. Charles led the effort to revamp and revitalize BD's Technology Leadership Development program as part of a broader initiative to provide a pipeline of talent for the company and has served as a leaderteacher of BD leadership training courses.

Charles has been with BD since 1988. From 1988 to 1997 Charles was Vice President of R&D for BD's Hypodermic and Injection Systems business. During this period, Charles initiated and led the major product development work that was done for BD’s highly successful healthcare worker needle stick prevention safety products, IV flush platform and a market appropriate catheter for China. These projects and others Charles was instrumental in championing and leading throughout his career at BD have created billions of dollars in annual revenue for BD for many years, The China catheter has been and remains BD’s largest selling product in China.

Prior to joining BD Charles led the product development efforts for Millipore Corp in Bedford, Massachusetts.

Charles served on the Board of NC BIO the local affiliate of BIO, the national Biotechnology industry organization. NC BIO advocates on behalf of its member companies mostly locally in North Carolina. Charles served and was Chairman of the Board of Ibiliti a non-profit focused on supporting and growing the Med Tech industry in N C. Charles served as Chairman of the Board of the Singapore Bio Venture Center an incubator that was a joint venture between BD and Johns Hopkins Medical. He also served as a member of the Board of Synecor. Charles has a Ph.D and MA from Princeton University an MSE degree from Johns Hopkins University and a B Ch E degree from the City College of New York. Charles has numerous publications and has given many talks.

Charles is member of numerous professional organizations and engages in outside charitable and philanthropic efforts on behalf of the Juvenile Diabetes Research Foundation and Princeton University. He served 6 years as a board member of the Eastern North Carolina chapter of the JDRF.

Charles serves on advisory committees for the Chemical and Biological Engineering Department at Princeton, the Whiting School of Engineering at Hopkins, the Chemical and BioMolecular Engineering Department also at Hopkins. He is an Annual Giving fund raiser for Princeton.

Charles received an award from the Johns Hopkins University for distinguished alumni service. Charles received several awards from the Juvenile Diabetes Research Foundation for service to that organization as well. At BD Charles has received highest level company awards for Technology Leadership, Innovation and Lifetime Achievement.

Randall Kaye

Area of expertise: 
Biomedical
SSI Strategy, Avanir Pharmaceuticals, Johnson & Johnson, InterMune, Pfizer, Axsome Therapeutics
Year Served: 
Bio 

Randall Kaye, MD serves as the Global Head of Medical Affairs at SSI Strategy, a boutique consulting firm focused on Medical Affairs, Pharmacovigilance and Clinical Development. In Dr. Kaye’s role at SSI Strategy, he focuses on providing a medical and scientific perspective to transformative initiatives in Medical Affairs and Pharmacovigilance. He plays a key role in SSI’s bespoke advisory services and regulatory compliance service offerings.

Most recently, Dr. Kaye was Chief Medical Officer at Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. While at Axsome, Dr. Kaye developed and executed all Clinical Research functional areas that resulted in the initialization of three clinical programs (IND Filing, FPI) in less than one year. Prior to joining Axsome, Dr. Kaye was Chief Medical Officer at Avanir Pharmaceuticals (acquired by Otsuka), a CNS specialty company. While at Avanir, Dr. Kaye provided leadership and vision to the clinical, regulatory and medical affairs areas, and supported the commercialization of new products from a medical, scientific, regulatory, technical and quality perspective. Prior to Avanir, Dr. Kaye served in a variety of medical affairs leadership positions at Scios Inc. (acquired by Johnson and Johnson) a cardiovascular specialty company, InterMune Inc. (acquired by Roche), a specialty company focusing on Idiopathic Pulmonary Fibrosis and Pfizer Inc.

Dr. Kaye earned his Doctor of Medicine, Masters in Public Health and Bachelor of Science degrees at The George Washington University in Washington, D.C. Dr. Kaye trained in Pediatrics at the University of Massachusetts Medical School and was a Research Fellow in Allergy and Immunology at Harvard Medical School.

Mahmoud Mahmoudian

Area of expertise: 
Biomedical
GSK, Eastman, Dow, Merck, Ferring Pharmaceuticals, Purdue Pharma
Year Served: 
Bio 

Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical, and chemical sectors. He joined Purdue Pharma in 2016 as Vice President, Head of Virtual Discovery business unit worldwide to incubate, build and commercialize an innovative R&D pipeline outside pain/ CNS. At Ferring Pharmaceuticals, he served as Vice President, Head of Innovative Medicines responsible for setting and delivering corporate strategy in immunotherapy, and external research. Prior to that, he was at Merck managing its External Research and R&D Operations in vaccines, biologics and biosimilars (Merck BioVentures) on a global basis. At Dow he was the Global Head of Biotechnology overseeing all of research and strategic alliances in five sites (US, UK, France, China, Japan) generating $600M sales. Dr. Mahmoudian was recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, partnering, managing growth, and development of its BioProducts portfolio. He launched his career with GlaxoSmithKline, where he held a variety of research, technology, and management roles of increasing responsibility in drug discovery, preclinical development and BioPharm R&D.

Dr. Mahmoudian has extensive hands-on scientific and operations experience leading international teams in R&D (discovery, preclinical, phase I-III), CMC, tech transfer, GMP biomanufacturing, and licensure of six blockbusters (Abacavir®, Epivir®, Lamuvidine®, Relenza®, Trizivir®, Zygara®) with $15B sales. He drives corporate and business development strategies to identify, incubate, or syndicate early/ late phase clinical assets, build NewCo and future R&D portfolio (cell therapies, vaccines, biologics, small molecules). He leads cross-functional scientific due diligence teams to scout, evaluate, and negotiate external innovations in products, platforms, academic alliances, and startups (40 deals) across multiple therapeutic areas (immunotherapy, cancer vaccines, immuno-oncology, rare diseases, microbiome, infectious diseases).

Arikha Moses

TyRx, Galatea Surgical
Year Served: 
Bio 

Arikha Moses, PhD, is a seasoned executive with 15+ years of experience creating and leading medtech companies. Dr. Moses started her career at a seed-stage venture firm, where she was responsible for sourcing, building, and managing early-stage life science companies including EluSys Therapeutics and TyRx. As TyRx’s Founder and Chief Scientific Officer, she was responsible for the company’s strategy and during her tenure she was involved in all aspects of the company’s business including financing, licensing, product development, corporate partnerships with Boston Scientific and Bard, and the commercialization of multiple drug-eluting devices. TyRx was sold to Medtronic for $160MM. She has also worked with the venture capital firm the Vertical Group as an EIR, where she assisted with due diligence on investments in both private and public companies. While working with Vertical, she founded and led Galatea Surgical, a plastic surgery company, through clinical studies and commercial product sales.

Arikha received a PhD in Chemistry from Yale University and a BA with Honors in Chemistry from Brandeis University.

Dev Shenoy

Area of expertise: 
Quantum/Neuromorphic Computing, Broad technical knowledge
Naval Research Lab, DARPA/MTO, Pentagon, DOE HQ
Year Served: 
Bio 

Dr. Dev Shenoy is currently the Chief Engineer for the Advanced Manufacturing Office (AMO) at the U.S. Department of Energy (DOE) Head Quarters.  Dev is a co-author of DOE’s 2015 QTR (Quadrennial Technology Review) that serves as a blueprint for DOE’s energy technology investments. Prior to joining DOE, he served as a Senior Advisor at the Manufacturing and Industrial Base Policy (MIBP) Office within the Office of the Secretary of Defense (OSD).  In that role he co-led a Telecom initiative with the White House Office of Science and Technology Policy (OSTP) to explore U.S. opportunities to strengthen the supply chain for optical networks and wireless equipment. 

Prior to serving at the Pentagon, Dev was a Program Manager at DARPA, (Defense Advanced Research Projects Agency), where he developed and managed over $100 M in cutting-edge technology programs for defense and commercial applications.  Dev’s DARPA programs included one on high power UV tunable lasers for Standoff Detection of Explosives; a program for tunable Electro-Optic devices based on non-linear optical materials for RF Photonics and near IR sensor protection; a program for a Hemispherical Array Detector (that mimics the retina in the eye) for wide field of view imaging in the visible and near IR; Electron spin based non-volatile memory for next-generation radiation hardened memory, a program to develop Non-Volatile Logic for instant-on and ultra-low power computing as well as a program for an ultra-sensitive Electric Field Detector for non-invasive detection of brain electric fields.   While at DARPA, Dev was also one of the judges at the DARPA Grand Challenge competition in 2007 for autonomous driving vehicles.

Prior to DARPA, Dev led several R&D projects at the Naval Research Lab (NRL) in Washington DC, where he was a Research Physicist/Project Manager.   Example projects at the NRL included synthetic nanopores for DNA sequencing; photo-polymerized monolayers for non-contact photo-alignment layers in Liquid Crystal Displays; laser actuated artificial muscles based on Elastomers; Information Displays for Liquid Crystals; Acoustic Sensor for underwater applications based on Ordered Nematic Fluids; and Pyro-electric sensors based on Ferro-electrics for next-generation thermal imaging applications. 

Dr. Shenoy obtained his Ph.D. in Physics from the prestigious Indian Institute of Science, Bangalore, India on Photon Correlation Spectroscopy of Binary Liquid Mixtures.  Dev then gained postdoctoral experience in Light Scattering from Polymer Systems in the Division of Macromolecular Science from Case Western Reserve University in Cleveland, OH and prior to NRL, served as Research Faculty in the Physics Department at the University of Nevada, Las Vegas.  

Dev has served on National Academy of Science panels and also presented at meetings organized by the White House OSTP on next-generation technologies that impact national security and economic competitiveness.   Dr. Shenoy has over 50 publications including in reputed journals such as Nature, and 5 issued patents.  Dev is a Fellow of the Society for Photonics Instrumentation Engineers (SPIE).

Ray Strimaitis

Area of expertise: 
intellectual property, patent strategy
Yahoo! Inc., Excalibur IP LLC, and IBM
Year Served: 
Bio 

Ray Strimaitis served as vice president of intellectual property and deputy general counsel for Yahoo! Inc. and vice president of Excalibur IP, LLC.  He led a global team of IP professionals and was responsible for all IP matters at Yahoo! and Excalibur.  As part of his role, Mr. Strimaitis was responsible for setting patent strategy, monetizing the Yahoo! and Excalibur patent portfolios, managing patent risk, guiding patent advocacy and overseeing all trademark/copyright matters. During his tenure at Yahoo!, Mr. Strimaitis successfully established and led a program to monetize Yahoo! patents that generated $600 million in patent sales and license transactions.  In 2016 he led the effort to form Excalibur IP, LLC – a wholly owned Yahoo! subsidiary that was created to further optimize patent value to Yahoo! shareholders. Under Mr. Strimaitis’s leadership, the Yahoo! IP department was recognized by the Association of Corporate Counsel as being among the industry’s top IP law departments and nominated for a Global Counsel Award in 2016. Before joining Yahoo!, Mr. Strimaitis served in various legal, management and patent monetization roles at IBM. He holds a BS in electrical engineering and a JD from Cleveland State University.

Past CTV Executives in Residence

Diego Carranza

Area of expertise: 
Biomedical
Forest Laboratories, Roche/Genentech
Year Served: 
Bio 

Diego is a global healthcare executive with 15+ years of progressive experience in the pharma/biotech industry. He has a diverse U.S. and international expertise in business development, commercial strategy & operations and marketing/sales execution. Diego has held positions of increasing responsibility at Roche/Genentech from 1999 to 2011 and Forest Laboratories from 2011- 2014. During his career, he has spearheaded numerous business development opportunities in a variety of deal structures including licensing/M&A/opt-ins that resulted in successful partnerships. Additionally, Diego has developed commercial strategies and coordinated operations for both for pharmaceutical & consumer health businesses, led both commercial & business development teams in a variety of disease areas/markets, integrated operations post-merger as well as directed restructurings globally. Diego holds a BA from University of Buenos Aires and a Master of Science in Industrial Administration (MBA) from Carnegie Mellon University – Tepper School of Business.

Bruce Conway

Area of expertise: 
Biomedical
CPG Consulting, Pars Pharmaceutical Consulting, Johnson & Johnson Pharmaceutical Research & Development
Year Served: 
Bio 

Bruce is the founder and CEO of CPG Consulting where he provides advisory services to Universities and emerging biotech/pharmaceutical companies. He serves as an independent consultant for Pars Pharmaceutical Consulting and as a Senior Advisor to several start-up companies. Bruce has over 18 years of R&D experience progressing projects from early discovery through the clinic. He has held positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research and Development (1996-2006) and The Institutes for Pharmaceutical Discovery (2006-2012). At J&J, Bruce presided over numerous high-profile projects including a novel program which led to an approved therapeutic for type 2 diabetes (Invokana™). Bruce has successfully executed and managed across diverse scientific functions (in vitro biology, in vivo pharmacology and ADME/DMPK) and he possesses a deep understanding of the Drug Discovery and Early Development processes. He also has significant expertise in the identification, evaluation and vetting of novel targets and technologies for incorporation into the R&D portfolio. He has served on cross-functional compound development- and life-cycle management teams in early development and has worked closely with academic scientists and key opinion leaders to assess start-up opportunities. Bruce holds a B.S. in Toxicology from the University of the Sciences in Philadelphia and a Ph.D. in Pharmacology from the Medical College of Virginia. He received postdoctoral training at the University of Massachusetts Medical Center. More detailed information can be found here.

 
 

 

Rick D’Augustine

Area of expertise: 
Biomedical
Cincytech, UMD Inc, Senmed Medical Ventures
Year Served: 
Bio 

Rick has over three decades of medical-industry experience in general management, venture capital investing and technology and business development in both public and private companies. He served as an Executive-in-Residence at Cincytech for almost four years through the end of 2011. Immediately prior to that, he served as president, CEO and a director of UMD Inc., a venture-backed drug-delivery company focusing on women’s health issues. Before joining UMD as its first employee, he spent five years as a group director at Senmed Medical Ventures, a private medical venture capital and business development firm. Rick spent 16 years with Johnson & Johnson and was a founding board member of Cincinnati-based Ethicon Endo-Surgery, initially serving as vice president of administration and CFO, and subsequently as vice president of business development. He was a founding board member of Enable Medical Corp., a private, high-technology medical device company, as well as Atricure Inc., an Enable spinoff focused on surgical treatment of atrial fibrillation, which is now a public company. He also serves or has served as a director on several company boards, including (locally)- Blue Ash Therapeutics, SpineForm, Ischemia Care and Enable Injections. He has a bachelor’s of science degree in mechanical engineering from Rensselaer Polytechnic Institute and an MBA in finance from Seton Hall University. More detailed information can be found here

 

Rana K. Gupta

Area of expertise: 
Biomedical
HistoRx, Navigator Technology Ventures, yet2.com
Year Served: 
Bio 

Rana Gupta has spent the last 12 years investing in and developing novel technologies. His passion for entrepreneurship is concentrated in entrepreneurial finance and technology development. Most recently, Mr. Gupta was CEO of HistoRx, a cancer diagnostics company and Yale University spin-out. He ran HistoRx for six years until selling it to Novartis AG in September 2012. Prior to HistoRx, Mr. Gupta was Managing Director at Navigator Technology Ventures (NTV), an early stage technology venture capital firm spun out of Draper Laboratory and based in Cambridge, MA. Six of NTV’s investments were laboratory or university spin-outs. Prior to his position with NTV, Mr. Gupta was Product Manager for Global Services with yet2.com, a B2B marketplace for technology transfer. Before yet2.com, Mr. Gupta founded IndoSine U.S. Link, Ltd., a business development company that helped clients expand international businesses between India, China, and the U.S. While running IndoSine, Mr Gupta co-founded a wireless software company, International Solutions, for which he served as Vice President of Sales and Marketing. Previous to IndoSine, he served as Manager, PRC Investment Strategy for Zeneca Pharmaceuticals in Beijing, China. At Zeneca, Mr Gupta was responsible for the China manufacturing strategy, for which he secured a $22M investment from the Board of Directors. For the last eight years, Mr Gupta has been teaching in BU’s entrepreneurship program in the areas of entrepreneurial finance and technology development. He holds an MBA in Finance and International Business from New York University's Stern School of Business, an MS in Operations Research from Stanford University, and a BA in Mathematics from Earlham College. More detalied information can be found here.

 

 

Barry Kappel

Area of expertise: 
Biomedical
ContraFect Corporation, Sapience Therapeutics
Year Served: 
Bio 

Barry Kappel is biotechnology entrepreneur and executive. He is driven to help develop and foster the biotechnology community in New York, and actively looks for technologies from New York-based academic institution that may potentially be developed into therapeutics. Most recently, Barry was a member of the founding team of ContraFect Corporation, which he joined in 2009 as the second employee. As the Senior Vice President of Business Development at a small biotechnology company, he was involved in all aspects of the company, including financing activities, licensing of the company's key technologies, establishing scientific collaborations with academic and corporate partners, presenting to regulatory authorities, and developing corporate strategy. ContraFect Corporation is now publicly traded (NASDAQ: CFRX) and has its first drug in human clinical trials. Prior to ContraFect, Barry was a Senior Consultant at Easton Associates, LLC, a boutique life science consulting firm located in Manhattan. In this capacity, he performed a wide range of activities, including the commercial assessment of preclinical and clinical compounds for Pharmaceutical and Biotechnology companies. Easton Associates has since been acquired by Navigant Consulting.

Barry received his B.A. in chemistry from Emory University, his Ph.D. in immunology and pharmacology from the Weill Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center, and his MBA from the S.C. Johnson Graduate School of Management at Cornell University.

Sam Kongsamut

Area of expertise: 
Biomedical
Rudder Serendip LLC, Sanofi
Year Served: 
Bio 

Sam has over 20 years of pharmaceutical R&D and business development experience at a succession of five different companies (Hoechst-Roussel Pharmaceuticals Inc, Hoechst Marion Roussel, Aventis, Sanofi-Aventis, now Sanofi), experiencing a company purchase, a merger of equals, a takeover, and a "transformation", all while remaining in Bridgewater, NJ. Sam managed various-sized groups of scientists in biochemical pharmacology that served multiple project teams in the neuroscience area, and was a member of the CNS Board that managed the CNS project portfolio. He led or worked on a variety of multi-disciplinary drug discovery and development projects covering a range of technologies and therapeutic indications in neuroscience and aging (OCD, anxiety-depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, sleep disorders, multiple sclerosis, spinal cord injury, stroke, hearing loss, pain, circadian rhythm disorders, urology, musculoskeletal disorders), helping to translate animal pharmacology to human pharmacology, including being involved with two marketed drugs that are now helping patients. From 2009-2012, Sam was Director of External Innovation at Sanofi-Aventis, using his experience to identify opportunities for collaboration and licensing for broad therapeutic interests within the Aging Unit. Since leaving Sanofi in 2012, Sam founded Rudder Serendip LLC, a consulting practice that serves clients at universities, foundations and biotechnology companies with advice on R&D plans and business development. Sam obtained a PhD at the University of Chicago and received postdoctoral training at Cornell and Yale Universities. More detailed information can be found here.

 

Jerry Korten

Area of expertise: 
Biomedical
GE, iSonea Medical, Versamed Inc
Year Served: 
Bio 

Jerry is a Medical Device Company Executive with expertise in product development, business development and regulatory approval planning. Previously the CEO of Versamed, Inc. which was sold to GE Healthcare where he served as GM for business development during the transition. He is now working as an advisor to investment bankers in the healthcare field and serves as a mentor to inventors in academia for the NYC Investment Fund. Jerry is a Director for iSonea Medical and has been a Director for three medical device companies. His technical expertise is in algorithm development using digital signal processing and instrumentation design with a focus on cardio-pulmonary measurements and embedded engineering design. More detailed information can be found here

Francis Lee

Area of expertise: 
Biomedical
GLG, McKinsey, Sanofi-Aventis
Year Served: 
Bio 

Francis leads the life-science Strategic Projects team at Gerson Lerhrman Group (GLG). In this role he helps clients generate strategic insights leveraging GLG’s expert network to help top hedge funds and private equity firms as well Fortune 500 corporations. Prior to GLG, Francis trained and specialized in psychiatry in the UK. He began his commercial career at Sanofi-Aventis which was followed by several years McKinsey & Co. He left to explore start-up opportunities and continued consulting for the life-science industry building his own client base and was recently asked to join GLG to help build their new consulting division which has now grown to a team of 8 people in less than one year. He has significant experience in life-cycle management through more than 7 product launches (over half were blockbusters) and evaluation of loss of expiration strategies for several brands; in particular he has a key strength in understanding medical levers to achieve commercial goals. Francis holds a MD and BSc from University of Birmingham, UK and a MBA from Columbia University.

Bob Sheehy

Area of expertise: 
Biomedical
Foundation Medical Partners, Genstar Capital, United Healthcare
Year Served: 
Bio 

Bob currently serves as an Executive Partner for Foundation Medical Partners and as a member of the Strategic Advisory Board for Genstar Capital. He is on the boards of Kips Bay Medical, Netsmart Technologies, Univita Health and Valence Health. He also serves as an advisor for Cognizant Technology Solutions and the University of Michigan School of Public Health. Bob began his career at Peak Health Plan, a small start-up which was acquired by United Healthcare. After progressing through a series of general management roles, he became CEO of United Healthcare in 2000. In this role, he was responsible for the strategy and results of United Health Group’s insurance and health plan operations. Bob retired from United Health Group in 2009. Bob has B.S. and M.H.S.A degrees from the University of Michigan.

 

Gordon Stewart

Area of expertise: 
Tech, Energy
Bell-Labs / Alcatel Lucent
Year Served: 
Bio 

Gordon has 20 years of diverse experience in intellectual property licensing, business development, and patent portfolio management, in both corporate and university settings. He has training and expertize in both the physical and life sciences. Prior to entering the business of intellectual property he was a researcher in pediatric genetics at the University of Michigan.

As Director of Global IP Strategy and Portfolio Management at Bell-Labs (Alcatel-Lucent), he managed a global portfolio of over 50,000 patent assets, interacting with attorneys, inventors, technical experts, and business units to ensure the portfolio was aligned to maximize value. He developed and implemented strategies to protect the IP of the company by monitoring the most important technologies and the most relevant geographies. He led teams in evaluating the portfolio to identify patents for use against third parties, both defensively and offensively, and those to be pruned for cost-savings purposes. In this role he also worked with Finance to help secure loans against the portfolio, and with M&A when portfolios were acquired or divested. He negotiated patent swaps, sales, and other ownership transactions with third parties. He worked with the company’s New Ventures Group on the intellectual property aspects of venture spin-offs.

Prior to that role, he managed the Data Processing and Multimedia portfolio segments, supporting deals in excess of $500M with major multinational companies. Gordon has personally negotiated licenses for patents and technology transfers in the areas such as superconductivity, imaging, biological research tools, and telecommunications.

Joining Bell Labs a licensing manager in the New Business Development group, he mined the deep and diverse patent portfolio for monetization opportunities in medical and other non-core areas. Gordon started his career in Technology Transfer at the University of Michigan (UofM) as an Associate Licensing Specialist.

Prior to moving to this business role Gordon was a research scientist in the department of pediatrics at UofM where he was also an associate at the Howard Hughes Medical Institute. His research was focused on the genetics of chromosome 21 and the development of genetic research tools. He has publications pertaining to chromosome 21, Down syndrome, Alzheimer’s disease, Huntington’s disease and murine situs inversus.

Gordon has an MBA from the University of Chicago, a PhD in Medical Genetics from the University of Glasgow, and a BSc in Biological Sciences (Genetics) from the University of Edinburgh. He also received postdoctoral training at Harvard Medical School.

More detailed information can be found here.

Natalie Tucker

Area of expertise: 
Biomedical
MELA Sciences
Year Served: 
Bio 

Natalie Tucker specializes in medical device commercialization and business development strategies. As the Director of Business Development for MELA Sciences Imaging Technologies, she is responsible for the strategy and results of software driven imaging products. MELA Sciences, Inc. is a medical device company that focuses on innovative medical technologies for physicians. Natalie emphasizes regulatory and reimbursement policies to drive product design and commercial success. She is a co-inventor of MELA Sciences Optical Spectral 3D Dermal Imaging System and also serves as a consultant to early stage medical device companies.

Natalie entered the field of medical device commercialization through the professional sports industry where she competed globally for eight years. She started and operated her own company where she consulted on business strategy and health management for clients. She worked in over 15 countries and was the feature of national advertising campaigns promoting future leaders.

Today, Natalie enjoys the opportunity to integrate emerging medical technologies with the needs and opportunities available in professional sports. Natalie received her B.S. in Kinesiology from Indiana University.

Lee Wrubel

Area of expertise: 
Biomedical
Egon Zehnder, Flare Capital Partners, Foundation Medical Partners, Highland Capital Partners, Canaan Partners
Year Served: 
Bio 
Lee brings more than two decades of venture capital experience to his role at Foundation Medical Partners and has a passion for healthcare information and medical technology companies. 
 
Prior to co-founding FMP in 2001, Lee served as an investment professional with Highland Capital Partners and Canaan Partners where he worked closely with the management of a large number of private companies. He began his business career as a consultant at The Wilkerson Group, a healthcare-focused management consulting company.
 
Lee currently serves on the Translational Research Advisory Committee of the Muscular Dystrophy Association and is a member of the Commercial Advisory Board of the Global Cardiovascular Innovation Center at the Cleveland Clinic. He is also a founder of the Coalition to Cure Calpain 3, a non-profit research organization founded to fund research into a rare form of muscular dystrophy.
 
Representative investments include CardioMEMS, Inc., Circulite, Inc., EndoGastric Solutions, Inc., IlluminOss, Rise Health, Atricure (NASDAQ: ATRC) and CardioNet (NASDAQ: CNET). 
 
Lee earned an A.B. from Lafayette College, an M.D. and Masters in Public Health from Tufts University, and an M.B.A. from Columbia University. Lee also completed a pediatric internship at Mount Sinai Medical Center in New York.
 

Jennifer Gabler

Area of expertise: 
Tech, Energy, Biomedical
The Refinery, Marlborough Street Partners
Year Served: 
Bio 
Jennifer Gabler is a Columbia MBA, CPA and has functioned as the CFO for multiple startup and venture backed companies. Her expertise is translating business plans of entrepreneurs into financial models that can be used to drive businesses forward operationally and engage financing sources. She could be particularly helpful to those Columbia ventures that have already launched and are looking to monetize their IP in a sustainable business model. She will assist companies with modeling their revenue/gross margin, projecting their P&L and balance sheet and sizing up cash requirements under different assumptions. She can also assist Columbia ventures in locating potential sources of capital. She can assist Columbia ventures in the initial set up of their legal and accounting structure, capitalization table modeling, management reporting, internal controls and management of human resources. Her focus is to assist companies in the management of back office operations, allowing the entrepreneurs to focus on developing their IP and customer facing aspects of their business. Her industry experience spans biotech, digital ventures, software and services, engineering/hardware applications, ad/media and customer facing/retail offerings, among many others.  
 
Jennifer has and AB from Dartmouth College, an MBA from Columbia University and has worked as an independent researcher for Harvard Business School on the topic of “Controls and Governance in Private Companies.” She has been a lecturer at Harvard and Tuck Business Schools.  She is part of a CXO consulting group, Marlborough Street Partners, which helps evaluate, revitalize, operate and monetize venture-funded companies.  Her most recent startup is as Co-Founder of The Refinery which is an accelerator for women owned businesses. She is well networked in the CFO, venture and angel investor communities. Jennifer loves “building it from scratch” and is eager to meet with Columbia entrepreneurs.  More information can be found here.
 

Javier Saade

Area of expertise: 
Tech, Energy, Biomedical
US Small Business Administration, GEM Group, Paradigm Ventures
Year Served: 
Bio 

Javier Saade was appointed by the President to be U.S. Small Business Administration’s Associate Administrator, Office of Investment and Innovation (“OII”). He left his post on October 30, 2015. He led the Small Business Investment Company (SBIC), Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR) and the Growth Accelerator Fund Competition programs. He holds a seat on the U.S. Securities and Exchange Commission’s Committee on Small & Emerging Companies appointed by Chairwoman White. His portfolio included: 1) capitalizing thousands of high-growth small businesses and entrepreneurial ecosystems, 2) investing billions of R&D dollars across a broad swath of America's STEM-driven innovation economy, 3) enhancing capital formation paths where investment gaps are widest, and 4) providing thought leadership on a broad set of economic issues which in turn drove making policy and executing agenda priorities.

Key multiagency collaborations he led or was instrumental to included USPTO’s Fast-Track Intellectual Property, Advanced Manufacturing Investment, JOBS Act Education, Diverse Asset Management, Rural Investing, Social Innovation, Impact Investing, Clean Energy Investing, and STEM Entrepreneurship. He regularly worked with Congress and the White House on policies that directly affect high growth small businesses across the country.

Before joining the Obama administration, Javier was in the private sector and has over 20 years of global principal investing, general management, strategic consulting and entrepreneurial experience. He was Managing Director at The GEM Group an emerging markets focused principal investing firm (PE|VC|HF) and a Principal at Paradigm Ventures, a venture capital firm. He was also an institutional client advisor at Bridgewater Associates, the largest hedge fund in the world with about $160 billion in assets. Javier spent his foundational career years as a strategy consultant at two firms, McKinsey & Company and Booz | Allen | Hamilton and held several operational, line management and engineering roles at life sciences giant Abbott Laboratories.

He enjoys building new companies, and has co-founded and been a top executive of three: a media broadcasting network, Air America Radio, a solar energy services company, Atenergy and a marketing & branding agency, Brand Maestro. Just prior to his public service, Javier advised two investment firms: Pacific Community Ventures, a $100 million double-bottom line and mission-driven impact VC firm in San Francisco and Aspen Grove Capital a $1.3 billion family office in Vail. He holds an MBA from Harvard, an MS in Operations & Technology from Illinois Institute of Technology, and a BS in Industrial Management & Manufacturing Engineering from Purdue University.

Adam Siegel

Area of expertise: 
Tech, Energy
Amazon, Fluid, Google [X], Booz & Company
Year Served: 
Bio 

Adam is a serial entrepreneur who has spent the past 10 years developing and launching new companies focused on the interface of computing, electronics, and healthcare. His passion for entrepreneurship focuses on the "lean startup", a method that centers on early customer engagement and hypothesis-driven product development. He is currently CEO and co-founder of Fluid, a mobile health company focused on urology and infectious disease that participated in the fifth class (v5) of the Rock Health accelerator in San Francisco in 2013. Prior to Fluid, he worked at Google [X], where he directed needs assessments and business development for new projects, including Google Glass and the Smart Contact Lens projects. Before Google, he was a management consultant for Booz & Company in Europe and the US, serving Fortune 500 companies in the life sciences and consumer products industries. From 2002-2009, Adam was a Howard Hughes Medical Institute Fellow in the George Whitesides Group at Harvard University, where he co-authored nine publications and eight patent applications, and designed devices that became the founding technologies for Claros Diagnostics (acquired by Opko in 2011) and Diagnostics-for-All, a social enterprise building medical tools for resource-limited settings. Adam hold a B.S. in Electrical Engineering from the University of Michigan, and a Ph.D. in Engineering and Applied Sciences from Harvard. He was a Fulbright Scholar to Germany from 2001-2002. More detalied information can be found here.

 

 

Brian P. Phillips

Area of expertise: 
Tech, Energy
TechnoServe, IBM
Year Served: 
Bio 

Brian is a serial technology entrepreneur who now specializes in helping entrepreneurs create, build, and grow their companies. As an entrepreneur, mentor, advisor, CEO, and board member, Brian has worked across a wide range of industries including B2B and B2C software, life sciences and biotech, government / defense industry, manufacturing, supply chain / distribution, agribusiness, and retail. He has worked in 30+ countries on five continents, with strong knowledge of emerging market economies and international business development. Brian has personally been involved in the early stages of a dozen companies, five of which eventually had an exit (two went public, two were acquired, and one was sold via a management buy out). He has raised over $28 million in venture capital. In addition, he launched a new enterprise software division within IBM and was a consulting manager in the Tech practice at Arthur Young & Company (now Ernst & Young). Most recently Brian served for three years as the Global Entrepreneurship Director for TechnoServe, an international nonprofit organization that specializes in economic development in emerging markets. At TechnoServe, Brian was responsible for providing growth services and developing access to finance for over 60,000 SME entrepreneurs globally. As part of this work, Brian has played a leadership role in promoting women’s economic development and female entrepreneurship in emerging economies. Brian serves on the Aspen Institute’s ANDE women’s entrepreneurship task force, which he co-founded. He is an advisor to the United Nations High Commission for Refugees (UNHCR), and has worked with both the U.S. and a number of international governments. He has partnered with and advised a number of multinational corporations including Goldman Sachs, Coca-Cola, Nike, MasterCard, and Walmart, and works closely with the Clinton Foundation. Brian has a passion for bringing good ideas to fruition, for making productive connections, and for leveraging his experience to help entrepreneurs succeed. More detailed information can be found here

 

George Cigale

Area of expertise: 
Tech, Energy
Tutor.com, Teachers College
Year Served: 
Bio 

George Cigale founded Tutor.com in 1998 and served as its CEO until 2013. Under George's leadership, Tutor.com became the leading provider of on-demand instructional solutions for students and professionals, with a proprietary technology platform that connects students and professionals to experts for on-demand and personalized help. Students have turned to Tutor.com over 10 million times and counting. Tutor.com was acquired by IAC/InteractiveCorp (NASD: IACI) in December 2012, and George became its Chairman in 2013. Before founding Tutor.com, George spent 15 years in education, software, and Internet industries, including executive positions at The Share Group, Adizes Institute, and The Princeton Review. George has raised over $35MM is venture capital. Since the acquisition of Tutor.com, George founded Abenaki Ventures, an advisory firm providing strategic services for early stage and growing education and internet companies. George serves as a Trustee on the Board of Columbia University Teachers College, and as a Member of the Advisory Council for Johns Hopkins Medicine, Institute for Basic Biomedical Sciences. George previously served on the Boards of Poets House and SIIA Education Division, and Chaired the National Advisory Council for the Johns Hopkins University School of Education. George received a BA in Political Science from the State University of New York at Binghamton, and currently lives in Pleasantville, New York, with his wife and three children. His blog can be found at http://ceotutor.blogspot.com/ and tweeting @gcigale.

Robert Colao

Area of expertise: 
Tech, Energy
radiusIP, Nokia, IBM
Year Served: 
Bio 

Robert Colao is the founder of radiusIP, Inc. - an Intellectual Property consulting and licensing services company serving a client base which includes Fortune 100 companies and individual inventors. radiusIP provides a broad set of IP services addressing client’s IP needs and issues including patent licensing, licensing program development, patent sales and acquisitions, IP negotiations, patent portfolio analysis/development, technology licensing - as well as other areas relating to effective management and monetization of IP. From 2008 to 2012 as Director of Outbound Patent Licensing at Nokia Inc., Bob led the company’s global outbound patent licensing activities/organization. Upon first joining Nokia in 2008 as Director of Patent Licensing, he also formulated and directed the business development of new opportunities expanding the licensing and monetization of the Nokia patent portfolio beyond the mobile handset space. Additionally, he drove the IP elements of numerous Nokia M&A activities (e.g. joint ventures and divestitures), which included the divestiture of Nokia’s wireless modem business. From 2000 to 2008, Bob was with IBM’s Corporate Intellectual Property Licensing organization and held the position of Director of International Licensing. His responsibilities at IBM included: the licensing of patents, technology and copyrights; IP related M&A (divestiture) activities and negotiations; patent pool participation (DVD-6C); as well as leading and establishing IBM’s patent sales process. Prior to 2000, Bob held management positions at IBM which included: hardware and software development in the area of high performance computing; marketing & business development; and strategy & planning. Bob holds a BS/MS in Electrical Engineering from Union College, as well as an MBA. More detailed information can be found here.

 

Siddhartha (Sid) Dalal

Area of expertise: 
Tech, Energy
RAND Corporation, Xerox, Bell Laboratories
Year Served: 
Bio 

Siddhartha (Sid) previously served as the chief technology officer (CTO) at RAND Corporation and a professor at the Pardee RAND Graduate School. At RAND, he was responsible for creating and coordinating strategies and architecture for new technology research and platforms; and for developing potential paths to commercialization, including product licensing and development. Prior to this, Sid served as senior adviser to the RAND President on technology, launching a major initiative in “big data” research systems. He was also the principal technical architect behind a revolutionary early warning system developed by RAND for identifying toxic chemicals among tens of thousands of other compounds which resulted in a first ever spin-off from RAND. Before joining RAND in 2007, Sid was vice president of research at Xerox, in charge of Xerox's worldwide imaging and software services research. He has also worked at Bell Laboratories and at Bellcore/SAIC/Telcordia Technologies, where he served as Chief Scientist and Executive Director. Sid has coauthored over 100 peer reviewed publications and holds patents related to software and network engineering and testing, machine learning, risk analysis, data/document mining, and statistical and econometrics modeling. He is also currently on the board of a start up, Praedicat Inc. Dalal received his B.S. from the University of Bombay and his M.B.A. and Ph.D. from the University of Rochester. More detailed information can be found here.

 

 

Shane Eten

Area of expertise: 
Tech, Energy
Feed Resource Recovery
Year Served: 
Bio 

Shane Eten is a successful entrepreneur with a passion for creating and capitalizing on sustainable business opportunities. Shane has a proven track record of developing industry disruptive solutions, closing complex sales with fortune 50 clients and building teams capable of delivering customers long-term value. For the past eight years, Shane has focused his efforts on leveraging proven and efficient technologies (both CleanTech and Web-based) to create a business model capable of redefining the waste industry. Today, this profitable venture—Feed Resource Recovery, Inc—designs, deploys and operates food-waste digestion facilities for some of the largest food retailers in the world. As the majority shareholder and board of directors member, Shane is now directing his knowledge and expertise towards finding the next generation of opportunities within the space where business, technology and the environment converge. These days Shane is an active advisor/mentor to numerous start-ups and is frequently retained by VC and PE firms to consult on various projects. More detailed information can be found here.

 

 

David Murphy

Area of expertise: 
Tech, Energy
HP, Mercury Interactive, Asera, Tivoli / IBN, McKinsey, Kleiner Perkins, Blue Coat Systems
Year Served: 
Bio 

David Murphy, CTV’s “Founding XIR”, returns to Columbia after completing a several year stint as Chief Operating Officer at Blue Coat Systems. David brings a diverse entrepreneurial experience and perspective that spans thirty years:

  • President & COO, Blue Coat Systems, acquired by Bain Capital from Thoma Bravo
  • BU GM Laser Jet and Enterprise Software, HP Printer Division
  • EVP Corp Dev and later CFO, Mercury Interactive, acquired by HP
  • President, Tivoli Software, after acquired by IBM
  • McKinsey Partner, technology, growth industry focused
  • MBA - Stanford
  • Schlumberger (field engineering)
  • BSCS/MSEE - U. Louisville/Florida Atlantic U.

Currently David focuses on proprietary and angel investment opportunities. He serves on several venture boards and advisories. He is particularly adept regarding technology translation, execution on product adoption and practical growth planning. David is most often seen at 30,000 feet - flying somewhere out in the marketplace to sell a new customer on enterprise technology. At sea level, David is an avid runner, and always good for a debate or competition.

William Reinisch

Area of expertise: 
Tech, Energy
Paladin Capital Group, XIV River, Motorola
Year Served: 
Bio 

William Reinisch is a Venture Partner with Paladin Capital Group, a Venture Capital firm, where he is responsible for sourcing and managing venture investments and runs the firm’s New York office. Reinisch is also currently the CEO and Founder of XIV River Consulting LLC. XIV River Consulting specializes in strategy, venture capital, technology, due diligence and innovation for, among others, high tech startups and companies that are pioneering new markets, and venture capital firms. Reinisch is also an Adjunct Professor at Columbia University, New York University, Fashion Institute of Technology and Stevens Institute of Technology. Reinisch previously served as the Vice President in Motorola’s strategy and technology organization. In this role, he was responsible for positioning Motorola for growth in emerging new market segments in addition to intellectual property, standards and the corporate technology portfolio. He was also part of Motorola Ventures, which is Motorola’s corporate venture capital group. Prior to that, Reinisch was vice president of strategy and new initiatives at Motorola. He joined Motorola in 2004 as a strategic advisor to the Chief Strategy Officer, working to define and develop technology, intellectual property and investment strategies for the corporation. Prior to joining Motorola, Reinisch was Senior Vice President of operations and engineering at Magnolia Broadband, where he led efforts in engineering, operations and radio frequency integrated circuit development until 2004. Before that, he led the global technology organization at Multilink Technology Corporation, a company focused on high-speed component solutions for advanced optical networks. Reinisch has also held various positions at ANADIGICS, Inc., including manager of strategic technology alliances. Prior to 1992, he worked for Analog Devices in the company’s semiconductor division. Experienced in many different aspects of the industry in both technology and operations, Reinisch has authored several publications, presentations, and six U.S. patents. He holds a master of business administration degree from Fordham University and a bachelor’s degree in microelectronic engineering from Rochester Institute of Technology.

Wim Sweldens

Area of expertise: 
Tech, Energy
Alcatel-Lucent, Bell Labs
Year Served: 
Bio 

Wim was most recently the President of Alcatel-Lucent’s Wireless Division, where he led the global development and deployment of LTE 4G technology and oversaw the introduction of the award-winning lightRadio small cell portfolio. Earlier in his role as VP of Network Technology, Wim took the company’s Applications Enablement strategy from paper to practice, allowing service providers to open and leverage their networks for the development of new services and applications. As founder and leader of Alcatel-Lucent Ventures, a strategic new business incubator and investment division inside of Bell Labs, Wim managed the lifecycle - from concept to commercialization - for eight ventures, ranging from enterprise and consumer applications to groundbreaking mobile innovations for operators. Wim also developed several compression algorithms including the one used in the JPEG2000 standard. He authored and co-authored several top cited technical papers, was a member of MIT Technology Review's inaugural class of top young innovators (1999 TR100), and was selected by Global Telecoms Business for its "Power 100 of 2009” list. He is a fellow of the IEEE and member of the Royal Belgian Academy of Sciences. Wim received his PhD in Computer Science from the University of Leuven, Belgium. He lives with his family in New Jersey. You can follow him on twitter @wimsweldens. More detailed information can be found here.

Kathy Timko

Area of expertise: 
Tech, Energy
Virendia LLC, Canoe Ventures, IDT Telecom
Year Served: 
Bio 

Kathy is the founder and CEO of Virendia, LLC where she provides advisory and consulting services to emerging and mid-stage, technology-focused companies. She holds key management and Advisory Board roles in several NY-based start-ups focused on Social Network Engagement, Personalized Online Career Resources, Crowd-sourced News Reporting, and Social Media Marketing for local businesses. In 2009, Kathy was appointed Chief Operating Officer of Canoe Ventures and became interim CEO in 2011. Canoe Ventures, a joint venture of the six leading cable companies, was formed to provide TV networks, advertising agencies and brand managers access to national advanced advertising products and media analytics. Before joining Canoe, Kathy held several senior management positions at IDT, serving as COO and CTO of IDT Telecom where she oversaw the unit's more than $2B retail and wholesale businesses, Kathy also served as COO of Carrier Services and was appointed to the IDT Telecom Board of Directors in 2001. Prior to IDT, Kathy was the EVP of Development and Operations at Call Sciences, a start-up company focused on Personal Number Services, and worked on communications and software systems at Bellcore, and Bolt, Beranek and Newman (BBN). From 2006 - 2010, Kathy served as an independent director on the board of Motionbox, Inc. She holds a B.S. in Mechanical Engineering from Virginia Tech and an M.S. in Computer Science from Boston University. More detailed information can be found here.

Nicholas Wood

Area of expertise: 
Tech, Energy
Emosyn LLC (Silicon Storage Technology), ATMI, Intel
Year Served: 
Bio 

Nicholas was the CEO and founder of Emosyn LLC, a fabless semiconductor company in the smart card and security markets. In April 2005 Nicholas sold the company to Silicon Storage Technology after growing the business to $60m on an annualized basis with 16 patents issued. Prior to founding Emosyn, he was V.P Marketing for ATMI Inc, a semiconductor materials company. Nicholas also spent 10 years with Intel Corporation in Europe. He has a BSc (Honours) in Electrical and Electronic Engineering from University of Manchester Institute of Science and Technology.